Skip to main content

Waters Posts 15-Percent Surge in Q3 Sales; US, Asia Markets Help Growth

NEW YORK, Oct. 26 (GenomeWeb News) - Waters today reported a 15-percent spike in third-quarter sales across its product portfolio, resulting in increased revenues and earnings.


Total receipts for the quarter ended Sept. 30 totaled $264.8 million, up from $230.4 million during the same period one year ago. These results reflect strong demand from US and Asian pharma and industry for all Waters product, as well as improved business conditions in Europe, according to the company.


Third-quarter R&D spending increased to $17 million from $15.1 million last year.


Waters' net income for the quarter increased to $51.9 million, or $.43 per basic share, from $36.4 million, or $.30 per basic share.


As of Oct. 2, Waters had $471.2 million in cash and cash equivalents.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.